Select Medical Holdings Corp Dossier - Source-backed chat

Select Medical Holdings Corp

SEMNYSE

SectorHealth services

IndustryHospital/Nursing Management

Beta (adjusted)0.86

Intrinsic Value $17.52median of 3 methodsbased on filings through 31 Mar 2026

Market Price $16.51Price as of 30 Jun 2026

Near fair valueIntrinsic value is 6% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2B

Enterprise Value $3.9B

Shares Outstanding 117.1M diluted

Moat Rating Narrow

Last ex-dividend14 May 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Select Medical Holdings Corp is currently in the process of being acquired by a consortium led by its co-founder and Executive Chairman, Robert A. Ortenzio, alongside Martin F. Jackson and Welsh, Carson, Anderson & Stowe (WCAS). The definitive take-private agreement, announced on March 2, 2026, values the company at $16.50 per share in cash, representing an enterprise value of approximately $3.9 billion. Given that the stock is trading very close to the acquisition price of $16.50 and the transaction is expected to close in mid-2026 following the stockholder vote on June 26, 2026, a 'Hold' recommendation is appropriate. The transaction is not subject to a financing condition, reducing closing risk, though minor regulatory and shareholder approvals remain.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.50

Mean target$16.50

High · most bullish analyst$16.50

Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger is rejected by unaffiliated stockholders or blocked by regulatory authorities, causing the stock to fall back to its unaffected pre-announcement level of approximately $14.01.

Base CaseCentral scenario

The take-private transaction completes successfully in mid-to-late 2026 at the agreed-upon price of $16.50 per share. Unaffiliated shareholders receive $16.50 in cash, and the company is delisted from the NYSE.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Definitive take-private agreement at $16.50 per share provides a clear exit price and downside protection.
No financing condition attached to the merger, with committed debt financing led by J.P. Morgan and Wells Fargo.
Strong performance in the Inpatient Rehabilitation segment, which saw a 14% revenue increase in Q1 2026.

Key Investment Risks

Closing risk if unaffiliated stockholders vote against the merger at the Special Meeting on June 26, 2026.
Margin compression in the Critical Illness Recovery Hospital segment due to labor cost pressures and Medicare Advantage denials.
High leverage and towering debt load of approximately $1.9 billion, which recently triggered a credit downgrade to B+ by S&P Global.

Thesis Invalidation Triggers

Rejection of the merger agreement by a majority of unaffiliated stockholders.
Regulatory intervention or failure to obtain necessary healthcare regulatory clearances.
Material adverse effect on Select Medical's operations prior to closing that allows the consortium to terminate the agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.